{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-063369","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.010617+00:00","generated_at":"2026-06-08T03:42:37.958482+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aptevo Q3 2023 net loss $6.3M; cash $19.1M; funding extends runway into Q4 2024","bullets":["Net loss of $6.3M ($0.50 per share) vs $7.6M loss in Q3 2022; no revenue reported.","Cash and equivalents $19.1M at Sept 30; raised $7M via public offering and warrant exercises, with potential additional $9.2M.","R&D expenses $3.9M (down $0.6M); G&A $2.7M (down $0.6M) year-over-year.","ALG.APV-527 Phase 1 dose-escalation trial for solid tumors continues enrolling patients; APVO436 Phase 2 planning ongoing.","Cash runway expected into Q4 2024, allowing reach of clinical milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-063369","json":"https://secwatch.observer/filing/0000950170-23-063369.json","markdown":"https://secwatch.observer/filing/0000950170-23-063369.md","text":"https://secwatch.observer/filing/0000950170-23-063369.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000095017023063369/0000950170-23-063369-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000095017023063369/apvo-20231114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:42:37.958482+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"382d3fa9f97572661cf2b3e86cfe1a97a339b302","claim":"Aptevo Therapeutics Inc. reported the quarter ended September 30, 2023 results: net income net loss of $6.3 million or $0.50 per share, EPS $0.50 per share.","evidence_excerpt":"Aptevo had a net loss of $6.3 million or $0.50 per share for the three months ended September 30, 2023, compared to a net loss of $7.6 million or $1.50 per share for the corresponding period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017023063369/0000950170-23-063369-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Net income","value":"net loss of $6.3 million or $0.50 per share"},{"label":"EPS","value":"$0.50 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}